Stacey Allerton, 45, was diagnosed with stage four lung cancer in 2023, which revealed it had already metastasised to her brain and bones. Her life is an unflinching look at finding meaning, strength,...

Dr. Marcelo Negrao about KRAS in lung cancer - Young Lung Cancer Initiative / cancer, Lung cancer, Marcelo Negrao, MD Anderson Cancer Center, OncoDaily,

YouTube video by Young Lung Cancer Initiative

ALT: a man in a suit and tie says oh my god

Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecula...

YouTube video by Young Lung Cancer Initiative

Thoracic SMARCA4-deficient undifferentiated tumor (TSDUT) is a rare and quite new classification of primary pulmonary malignancy. It is classified as a non-small cell lung cancer, typically associated...

YouTube video by GRACE - Global Resource for Advancing Cancer Education

Cell Death Discovery - Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer

YouTube video by Young Lung Cancer Initiative

Dear Colleagues, A recent publication in the American Journal of Case Reports presents a significant case of a 49-year-old patient with ROS1 fusion-po...

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC)…

Bianca Bye, an advocate whose parents were diagnosed with non-small-cell lung cancer the same year, shares what she’s learned about treatments and resources.

CT scans can help radiologists and referring providers characterize radiation pneumonitis and provide patients with accurate information about benign post-treatment effects

YouTube video by Young Lung Cancer Initiative

Leptomeningeal metastatic disease (LMD) arises secondary to the metastatic dissemination of cancer cells into the leptomeninges and cerebrospinal fluid. Novel therapies against systemic disease have n...

Osimertinib resistance represents a significant challenge in the management of EGFR-mutant NSCLC. MET alteration is a common resistance mechanism and previous work has established that combination EGFR/MET inhibition may represent a viable treatment strategy in this population. There are emerging data suggesting that a combination of capmatinib and osimertinib (cap/osi) will be effective in this setting although prospective data is limited.

PURPOSEPatients with tumors harboring BRAF class 3 mutations lack targeted therapies. These mutations are characterized by low/absent BRAF kinase domain activation and are believed to amplify already ...